Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2025-08-14 Annual Report
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서) by PharmAbcine. In the South Korean regulatory context (DART system), a 'Business Report' is the equivalent of an Annual Report (10-K). The document contains detailed business descriptions, industry analysis, and market data, which are core components of an Annual Report. Since it is a formal correction to an existing annual filing, it is classified as an Annual Report (10-K). FY 2024
2025-08-14 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company '주식회사 파멥신' (PharmAbcine Inc.) covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business overviews, and management reports, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean
소송등의판결ㆍ결정 (위약벌청구의 소)
Legal Proceedings Report Classification · 100% confidence The document is a formal disclosure regarding a court judgment ('소송등의판결ㆍ결정') involving a lawsuit ('위약벌청구의 소'). It details the case name, court, judgment date, and the outcome of the legal proceedings. This falls directly under the category of legal proceedings and regulatory disclosures regarding litigation.
2025-07-11 Korean
기타경영사항(자율공시) (상장폐지결정효력정지 가처분 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from PharmAbcine regarding a legal action (an injunction application) filed against the Korea Exchange to suspend a delisting decision. While it relates to a delisting event, it is specifically a report on a legal proceeding (litigation) initiated by the company. Given the specific nature of the filing as a legal challenge to a regulatory decision, it fits best under 'Legal Proceedings Report' (LTR).
2025-05-28 Korean
주권매매거래정지 (투자자보호)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice regarding the suspension of stock trading for PharmAbcine due to investor protection concerns and pending court decisions on delisting. It is a formal regulatory announcement issued by the exchange, fitting the criteria for a general regulatory filing.
2025-05-28 Korean
기타시장안내 (정리매매 보류 관련)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice regarding the suspension of delisting procedures due to a court injunction. It does not constitute a full delisting report or a financial filing, but rather a regulatory announcement regarding market status. As it does not fit into specific categories like 'DLST' (which is for the announcement of the delisting itself) or 'LTR' (which is for legal proceedings reports), it falls under the general regulatory announcement category.
2025-05-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.